Inge von Alvensleben | Medicine and Dentistry | Best Researcher Award

Dr. Inge von Alvensleben | Medicine and Dentistry | Best Researcher Award

Dr. Inge von Alvensleben , Medicine and Dentistry at  Kardiozentrum , Bolivia

Inge Barbara von Alvensleben is a pediatric cardiologist based in La Paz, Bolivia. Born in Freiburg, Germany, on May 8, 1972, she completed her medical studies at Charité – Humboldt-Universität Berlin. She has dedicated much of her career to improving child healthcare, especially in underserved regions. With a background in pediatrics and pediatric cardiology, she has worked in diverse environments, including refugee camps in Iraq and prisons in Bolivia. Since 2018, she has been a pediatric cardiologist at Kardiozentrum and Fundación Cardioinfantil La Paz. Dr. von Alvensleben is passionate about advancing pediatric healthcare through research and clinical practice, focusing on congenital heart diseases and high-altitude health challenges. Her work is internationally recognized, with numerous publications in leading medical journals.

Publication Profile

Scopus

Academic Background🎓

Inge Barbara von Alvensleben completed her medical studies at Charité – Humboldt-Universität Berlin, Germany, from 1993 to 2000. She then pursued a residency in pediatrics at Neubrandenburg Hospital, Germany, from 2000 to 2003. In 2008, she earned a diploma in “Adolescence – Integral Health Approach” from Universidad Nacional del Comahue, Argentina. She further enhanced her expertise by completing courses in Basic Life Support (2011) and Pediatric Advanced Life Support (2011) from the American Heart Association. In 2013, she completed her thesis on the percutaneous closure of atrial septal defects at Munich, Germany. Her graduation in pediatric cardiology took place in 2018, in Frankfurt, Germany. These academic milestones have shaped her comprehensive expertise in both pediatric healthcare and cardiology, with a particular focus on high-altitude medicine and congenital heart disease.

Professional Background🏅

Dr. Inge Barbara von Alvensleben’s professional experience spans several countries and diverse clinical settings. After completing her pediatric fellowship at Bonhoeffer-Klinik Neubrandenburg (2000-2003), she volunteered as a pediatrician in a Kurdish refugee camp in Iraq (2004), providing care to displaced populations. In Bolivia, she worked at Hospital La Paz as an intern (2005-2006) before engaging in various volunteer projects, including serving as a pediatrician in La Paz prisons and working with street children (2006-2009). From 2009 to 2013, she worked as a pediatrician at Kardiozentrum and Fundación Cardioinfantil La Paz. She completed her pediatric cardiology residency at Kinderherzzentrum Giessen, Germany, from 2014 to 2018. Since November 2018, she has been practicing as a pediatric cardiologist at Kardiozentrum and Fundación Cardioinfantil La Paz, where she continues to care for children with congenital heart diseases and contribute to research in pediatric cardiology and high-altitude health.

Awards and Honors🏆

Throughout her career, Dr. Inge Barbara von Alvensleben has been recognized for her contributions to pediatric cardiology and healthcare. While specific awards are not listed, her work in pediatric cardiology, particularly in resource-limited settings, has earned her considerable recognition within international medical communities. She is highly respected for her research into the effects of high-altitude environments on pediatric health, especially regarding congenital heart disease. Her publications in esteemed journals, such as Hypertension and Cardiology in the Young, showcase the impact of her work in understanding and treating conditions in challenging environments. Her dedication to improving the health of children worldwide, especially in Bolivia, has brought her ongoing professional recognition. As a faculty member at medical conferences and contributor to international research projects, Dr. von Alvensleben continues to influence pediatric cardiology both in clinical practice and academic settings.

Research Focus🔬

Dr. Inge Barbara von Alvensleben’s research focuses on pediatric cardiology, with a particular interest in congenital heart diseases and the effects of high-altitude living on cardiovascular health. She has contributed to groundbreaking studies on the adaptation of children with congenital heart conditions living at high altitudes, such as those in Bolivia. Her work investigates the physiological challenges faced by newborns in high-altitude environments and how these conditions may affect the development of pulmonary hypertension and other cardiovascular issues. Dr. von Alvensleben has also researched the use of innovative interventional techniques, such as the percutaneous closure of atrial septal defects, and their impact on patient outcomes. Her work aims to improve the management and treatment of pediatric heart conditions, especially in low-resource settings. Through her research, she seeks to bridge the gap in pediatric healthcare between developed and developing nations, particularly in high-altitude regions.

Publication Top Notes

 Prolonged postnatal adaptation and enhanced prevalence of congenital heart diseases due to altitude may contribute to newborn mortality in Bolivia. Experimental Physiology.

Prolonged postnatal adaptation and enhanced prevalence of congenital heart diseases due to altitude may contribute to newborn mortality in Bolivia

Conclusion

Dr. Inge Barbara von Alvensleben is highly deserving of the “Best Researcher Award.” Her dedication to improving pediatric healthcare, particularly in challenging environments like Bolivia, demonstrates her unwavering commitment to advancing medical knowledge and patient care. She has proven her expertise through a series of influential studies, making her a trailblazer in pediatric cardiology. Her work continues to inspire both researchers and healthcare professionals globally, and she has significantly contributed to understanding the complexities of congenital heart diseases and their management in resource-limited regions. Her innovative approach, depth of knowledge, and passion for improving child health are qualities that make her a top candidate for this prestigious award.

 

 

Rainer Pooth | Medicine and Dentistry Award | Best Innovation Award

Dr. Rainer Pooth | Medicine and Dentistry Award | Best Innovation Award

Dr. Rainer Pooth, ICAAN GmbH, Germany

Based on the information provided, Dr. Rainer Pooth appears to be a highly suitable candidate for the “Research for Best Innovation Award” in the pharmaceutical and medical industry. Here’s an assessment of his qualifications:

Publication profile

Professional Experience & Leadership

Dr. Pooth has over 20 years of experience in the global pharmaceutical and medical industry, with a strong track record of leadership in multidisciplinary teams at both global and affiliate levels. His roles as Managing Director, Global Head of Medical/Scientific Affairs, and Head of Global Clinical Development demonstrate his ability to lead and innovate in complex, highly regulated environments. His strategic input in global R&D programs, project management, and regulatory affairs underscores his expertise in driving innovation and ensuring successful product development.

Achievements & Expertise

Dr. Pooth’s achievements include multiple approvals of medicinal products and medical devices across key global markets such as the EU, US, Australia, and Asia. He holds more than 35 patents, with a significant portion becoming commercially relevant, highlighting his innovative contributions to the field. His extensive publication record, including over 50 publications in international journals and books, as well as his role as an invited speaker at major scientific congresses, further cements his reputation as a leader in pharmaceutical research and innovation.

Global Impact & Collaboration

Dr. Pooth’s global network of experts and key opinion leaders, along with his experience in managing international submission teams and regulatory interactions, illustrates his ability to navigate and influence the global pharmaceutical landscape. His leadership in directing high-level global teams and managing collaborations with regulatory authorities and contract research organizations (CROs) demonstrates his capability to bring innovative products to market successfully.

Publication Top Notes

  • “Treatment of Refractory Cardiac Arrest by Controlled Reperfusion of the Whole Body” – A study exploring CARL in a multicenter setting, highlighting its impact on refractory cardiac arrest patients (2023).
  • “The Impact of Head Position on Neurological and Histopathological Outcome Following CARL” – Investigates how head positioning affects outcomes in a pig model during CARL (2023).
  • “Extracorporeal Cardiopulmonary Resuscitation—Evidence and Implications” – Discusses ECPR’s evidence base and its clinical implications (2023).
  • “Effects of Prolonged Serum Calcium Suppression during ECPR in Pigs” – Examines the effects of serum calcium suppression during ECPR, showing implications for treatment strategies (2023).
  • “Limiting Calcium Overload after Cardiac Arrest” – Focuses on the role of albumin in reducing calcium overload during CARL (2023).
  • “Pervasive Platelet Secretion Defects in SARS-CoV-2 Patients” – Analyzes platelet defects in COVID-19 patients and their potential implications for treatment (2023).
  • “CARL – Controlled Reperfusion of the Whole Body” – A book detailing the CARL procedure, providing a comprehensive resource for clinicians (2022).
  • “Observational Study on Implications of the COVID-19-Pandemic for Cardiopulmonary Resuscitation” – Examines the pandemic’s impact on resuscitation practices, offering valuable insights (2022).
  • “Monitoring Mitochondrial Partial Oxygen Pressure During Cardiac Arrest and ECPR” – A pilot study exploring mitochondrial oxygen monitoring during cardiac arrest in a pig model (2021).
  • “Brain Vulnerability and Viability after Ischaemia” – A review on the neurological outcomes following ischemic events, highlighting vulnerabilities and potential treatment avenues (2021).

Conclusion

Dr. Pooth’s extensive experience, significant contributions to the development and approval of innovative pharmaceutical products, and his leadership in global research and development make him a strong candidate for the “Research for Best Innovation Award.” His work has had a substantial impact on multiple therapeutic areas, including dermatology, immunology, aesthetic medicine, oncology, and neurology, making him well-deserving of recognition in this prestigious category.